Literature DB >> 7955174

Inhibition of integrin function by a cyclic RGD-containing peptide prevents neointima formation.

H Matsuno1, J M Stassen, J Vermylen, H Deckmyn.   

Abstract

BACKGROUND: RGD-containing peptides are able to prevent binding of ligands to certain integrins such as alpha IIb beta 3 (glycoprotein IIb/IIIa) and alpha v beta 3 and as such are inhibitors for platelet aggregation and smooth muscle cell migration, both of which are involved in neointima formation. METHODS AND
RESULTS: Hamster carotid arteries were damaged, and neointima formation was determined at different time points. G4120, a cyclic RGD-containing peptide, was administered continuously intravenously by an implanted osmotic pump. Neointima formation was inhibited dose dependently. The inhibition was strongest when treatment was started before the vascular injury and continued for the full observation period. Treatment started after the damage and maintained until neointima assessment or started before and stopped earlier was less effective.
CONCLUSIONS: Inhibition of integrin function by an RGD-containing peptide results in reduction of the development of a neointima. This effect is due both to an early event, which could be due to inhibition of secretion of PDGF by the platelets with blocked alpha IIb beta 3, and to a late event, possibly by interference with smooth muscle cell alpha v beta 3.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7955174     DOI: 10.1161/01.cir.90.5.2203

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  21 in total

1.  Regulation of smooth muscle cell migration and integrin expression by the Gax transcription factor.

Authors:  B Witzenbichler; Y Kureishi; Z Luo; A Le Roux; D Branellec; K Walsh
Journal:  J Clin Invest       Date:  1999-11       Impact factor: 14.808

2.  Coordinated regulation and colocalization of alphav integrin and its activating enzyme proprotein convertase PC5 in vivo.

Authors:  Philipp Stawowy; Kristof Graf; Stephan Goetze; Mattias Roser; Michel Chrétien; Nabil G Seidah; Eckart Fleck; Mieczyslaw Marcinkiewicz
Journal:  Histochem Cell Biol       Date:  2003-02-20       Impact factor: 4.304

Review 3.  Antiplatelet therapy with glycoprotein IIb/IIIa receptor inhibitors and other novel agents.

Authors:  A I Schafer
Journal:  Tex Heart Inst J       Date:  1997

4.  Characterization of simple and reproducible vascular stenosis model in hypercholesterolemic hamsters.

Authors:  H Matsuno; O Kozawa; M Niwa; A Abe; Y Takiguchi; T Uematsu
Journal:  Lipids       Date:  2001-05       Impact factor: 1.880

Review 5.  Delivery of large biopharmaceuticals from cardiovascular stents: a review.

Authors:  Hironobu Takahashi; Didier Letourneur; David W Grainger
Journal:  Biomacromolecules       Date:  2007-10-12       Impact factor: 6.988

Review 6.  Dealing with in-stent restenosis.

Authors:  A H Gershlick; J Baron
Journal:  Heart       Date:  1998-04       Impact factor: 5.994

7.  Osteopontin overexpression in vascular smooth muscle cells transfected with the c-Ha-rasEJ oncogene.

Authors:  A R Parrish; T J Weber; K S Ramos
Journal:  In Vitro Cell Dev Biol Anim       Date:  1997-09       Impact factor: 2.416

8.  The inhibition of vascular smooth muscle cell migration by peptide and antibody antagonists of the alphavbeta3 integrin complex is reversed by activated calcium/calmodulin- dependent protein kinase II.

Authors:  C Bilato; K A Curto; R E Monticone; R R Pauly; A J White; M T Crow
Journal:  J Clin Invest       Date:  1997-08-01       Impact factor: 14.808

Review 9.  Perspectives series: cell adhesion in vascular biology. Smooth muscle migration in atherosclerosis and restenosis.

Authors:  S M Schwartz
Journal:  J Clin Invest       Date:  1997-06-15       Impact factor: 14.808

Review 10.  Platelet GPIIb/IIIa antagonists: the first anti-integrin receptor therapeutics.

Authors:  B S Coller
Journal:  J Clin Invest       Date:  1997-04-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.